News

September 18, 2009 – Patients’ response to anti-platelet therapy after percutaneous coronary intervention (PCI) and its impact on clinical outcomes will be covered in a TCT 2009 breakfast symposium starting at 6:30 a.m. Wedensday, Sept. 23 in room 121 at the Moscone Center in San Francisco.

Home September 18, 2009
Home
News

September 18, 2009 – Physicians at The Mount Sinai Medical Center in New York became the first in the U.S. to ablate atrial fibrillation (AF) using a visually-guided laser balloon catheter.

Home September 18, 2009
Home
News

September 18, 2009 – Boston Scientific today said it completed patient enrollment in the workhorse portion of its PLATINUM clinical program, a global, randomized, pivotal controlled trial designed to support FDA and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the platinum-chromium PROMUS Element Everolimus-Eluting Coronary Stent System.

Home September 18, 2009
Home
Technology

September 18, 2009 – The FDA has approved Valturna (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

Home September 18, 2009
Home
News

September 18, 2009 – Following the recent CE mark certification of the vProtect Luminal Shield, the novel self-expanding coronary stent system will be the focus of scientific presentations and roundtable discussions on lesion-specific therapy for coronary artery disease at TCT 2009, Sept. 21-25, in San Francisco.

Home September 18, 2009
Home
Feature | Dave Fornell

When vessels are stretched and ripped via angioplasty balloon expansion, the exposed soft muscle tissue can lead to the proliferation of scar tissue (neointimal hyperplasia) that can reocclude the vessel. Drug-eluting stents (DES) were introduced in 2003 to overcome this issue with anti-proliferative drugs, the same as used to prevent cellular growth in cancerous tumors.

Home September 17, 2009
Home
St. Jude Medical's Merlin@home transmitter
Feature | Dave Fornell

There is a growing trend in electrophysiology toward remote, home monitoring of implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, pacemakers and implantable cardiac monitors (ICMs).

Home September 17, 2009
Home
Feature | Richard R. Rogoski

A trend that was fueled by cardiologists wanting to gain a larger share of reimbursement fees, while at the same time providing more personalized care to their patients, is beginning to fizzle as reimbursements continue to be cut.

Home September 17, 2009
Home
Feature | Dave Fornell

Bare metal stents (BMS) were introduced in 1994 as an improvement over balloon angioplasty alone, which had a high restenosis rate of between 30-40 percent. The cobalt-chromium or stainless steel stents helped reduce restenosis, bringing rates down to about 15-20 percent, but BMS also increased the risk of early in-stent thrombosis shortly following the procedure.

Home September 17, 2009
Home
News

September 18, 2009 ¬– Abbott has announced the company's schedule of key news announcements and events during the Transcatheter Cardiovascular Therapeutics (TCT) 2009 conference in San Francisco, Sept. 21-25.

Home September 17, 2009
Home
News

September 17, 2009 – NMT Medical Inc. said yesterday it will commence data analysis for its landmark STARFlex patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) clinical trial, CLOSURE I, in April 2010 instead of its originally scheduled fall 2010, so it can accelerate its pre-market approval (PMA) submission to the FDA.

Home September 17, 2009
Home
News

September 17, 2009 – Boston Scientific Corp. announced its schedule of the company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Sept. 21-25, in San Francisco.

Home September 17, 2009
Home
News

September 17, 2009 – The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) on Wednesday featured four late breaking clinical trials.

Home September 17, 2009
Home
News

September 17, 2009 – Elixir Medical Corp. said today its stent systems using bioabsorbable polymers will be featured in multiple sessions at the 21st annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2009), Sept. 21-25, in San Francisco.

Home September 17, 2009
Home
News

September 17, 2009 – One of the activities at TCT 2009 is the Hearts in Hand Collection, a library of physical heart models in a variety of structural disease states, which allow physicians to gain quick and thorough understanding of spatial relationships and practice catheter pathways and device sizing prior to conducting minimally invasive interventions.

Home September 17, 2009
Home
Subscribe Now